文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

阿那白滞素与常规治疗对普通病房成人COVID-19轻中度肺炎疗效比较(CORIMUNO-ANA-1):随机对照试验

Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial.
PubMed 文献 · Lancet Respir Med · 2021-01-22
一句话结论阿那白滞素未改善普通病房成人COVID-19轻中度肺炎结局:第4天WHO-CPS>5比例36%对38%,第14天死亡或需通气47%对51%,均无显著差异。

CORIMUNO-ANA-1为法国16家大学医院开展的多中心、开放标签、贝叶斯随机临床试验,纳入无需通气支持、需至少3 L/min氧疗、WHO-CPS评分5分、CRP>25 mg/L的COVID-19轻中度肺炎住院成人116例,1:1随机接受常规治疗联合阿那白滞素(第1-3天200 mg每日两次,第4天100 mg每日两次,第5天100 mg每日一次)或单纯常规治疗。主要终点第4天WHO-CPS>5比例阿那白滞素组36%(21/59)对常规治疗组38%(21/55),绝对风险差中位数-2.5%(90%可信区间-17.1至12.0),阿那白滞素更优的后验概率61.2%;第14天死亡或需通气比例47%对51%,HR中位数0.97(90%可信区间0.62至1.52)。第90天死亡率两组均为27%,严重不良事件46%对38%(p=0.45)。结论为阿那白滞素未改善此类患者结局。

要点

  • 第4天WHO-CPS>5比例:阿那白滞素组36%(21/59)对常规治疗组38%(21/55),绝对风险差中位数-2.5%(90%可信区间-17.1至12.0),阿那白滞素更优的后验概率61.2%。
  • 第14天死亡或需通气:阿那白滞素组47%(95%CI 33至59)对常规治疗组51%(95%CI 36至62),HR中位数0.97(90%可信区间0.62至1.52),阿那白滞素有效后验概率54.5%。
  • 第90天死亡:阿那白滞素组27%(16例)对常规治疗组27%(15例),两组相同。
  • 严重不良事件:阿那白滞素组46%(27例)对常规治疗组38%(21例),p=0.45。
  • 研究因数据与安全监查委员会建议提前终止,实际纳入116例(阿那白滞素组59例、常规治疗组57例)。

适用人群与场景

  • 法国16家大学医院住院的成人COVID-19轻中度肺炎患者,经实时RT-PCR确诊SARS-CoV-2感染。
  • 纳入条件:需面罩或鼻导管至少3 L/min氧疗但无需通气辅助,WHO临床进展量表(WHO-CPS)评分5分,血清C反应蛋白>25 mg/L,入院时不需要入住重症监护室。

诊断标准与关键阈值

  • WHO临床进展量表(WHO-CPS)评分5分作为入组条件;主要终点之一为第4天WHO-CPS评分>5分(即死亡或需无创或有创机械通气)。
  • 血清C反应蛋白>25 mg/L为入组条件之一。

处置流程与药物剂量

  • 阿那白滞素组:在常规治疗基础上,第1-3天200 mg每日两次,第4天100 mg每日两次,第5天100 mg每日一次。
  • 常规治疗由各中心临床医生自行决定。
  • 随机分组为1:1,使用基于网络的安全集中化系统,按中心分层,区组长度随机为2或4。

研究设计与关键结果

  • 多中心、开放标签、贝叶斯随机临床试验(CORIMUNO-ANA-1),嵌套于CORIMUNO-19队列,法国16家大学医院,纳入116例(阿那白滞素组59例、常规治疗组57例),常规治疗组2例撤回知情同意未纳入分析。
  • 2020年4月8日至4月26日筛查153例,数据与安全监查委员会建议后研究提前终止,实际招募116例。
  • 可分析人群年龄中位数66岁(IQR 59至76),男性80例(70%)。
  • 主要终点第4天WHO-CPS>5:阿那白滞素组21/59(36%)对常规治疗组21/55(38%),绝对风险差中位数-2.5%(90%可信区间-17.1至12.0),阿那白滞素更优的后验概率61.2%。
  • 第14天死亡或需通气:阿那白滞素组28例(47%;95%CI 33至59)对常规治疗组28例(51%;95%CI 36至62),HR中位数0.97(90%可信区间0.62至1.52),阿那白滞素有效后验概率54.5%。
  • 第90天死亡:阿那白滞素组16例(27%)对常规治疗组15例(27%)。
  • 严重不良事件:阿那白滞素组27例(46%)对常规治疗组21例(38%),p=0.45。
  • 所有分析均按意向治疗进行。

证据类型、等级与局限

  • 证据类型:多中心、开放标签、贝叶斯随机临床试验。
  • 研究因数据与安全监查委员会建议提前终止,实际样本量116例。
  • 局限:研究提前终止;作者指出需进一步研究评估阿那白滞素在其他特定更严重COVID-19患者群体中的疗效。

对床旁实践的改变

  • 作者结论:阿那白滞素未改善COVID-19轻中度肺炎住院患者的结局。
  • 作者认为需进一步研究评估阿那白滞素在其他特定更严重COVID-19患者群体中的疗效。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Patients with COVID-19 pneumonia have an excess of inflammation and increased concentrations of cytokines including interleukin-1 (IL-1). We aimed to determine whether anakinra, a recombinant human IL-1 receptor antagonist, could improve outcomes in patients in hospital with mild-to-moderate COVID-19 pneumonia.

METHODS: In this multicentre, open-label, Bayesian randomised clinical trial (CORIMUNO-ANA-1), nested within the CORIMUNO-19 cohort, we recruited patients from 16 University hospitals in France with mild-to-moderate COVID-19 pneumonia, severe acute respiratory syndrome coronavirus 2 infection confirmed by real-time RT-PCR, requiring at least 3 L/min of oxygen by mask or nasal cannula but without ventilation assistance, a score of 5 on the WHO Clinical Progression Scale (WHO-CPS), and a C-reactive protein serum concentration of more than 25 mg/L not requiring admission to the intensive care unit at admission to hospital. Eligible patients were randomly assigned (1:1) using a web-based secure centralised system, stratified by centre and blocked with varying block sizes (randomly of size two or four), to either usual care plus anakinra (200 mg twice a day on days 1-3, 100 mg twice on day 4, 100 mg once on day 5) or usual care alone. Usual care was provided at the discretion of the site clinicians. The two coprimary outcomes were the proportion of patients who had died or needed non-invasive or mechanical ventilation by day 4 (ie, a score of >5 on the WHO-CPS) and survival without need for mechanical or non-invasive ventilation (including high-flow oxygen) at day 14. All analyses were done on an intention-to-treat basis. The trial is registered with ClinicalTrials.gov, NCT04341584, and is now closed to accrual.

FINDINGS: Between April 8 and April 26, 2020, we screened 153 patients. The study was stopped early following the recommendation of the data and safety monitoring board, after the recruitment of 116 patients: 59 were assigned to the anakinra group, and 57 were assigned to the usual care group. Two patients in the usual care group withdrew consent and were not analysed. In the analysable population, the median age was 66 years (IQR 59 to 76) and 80 (70%) participants were men. In the anakinra group, 21 (36%) of 59 patients had a WHO-CPS score of more than 5 at day 4 versus 21 (38%) of 55 in the usual care group (median posterior absolute risk difference [ARD] -2·5%, 90% credible interval [CrI] -17·1 to 12·0), with a posterior probability of ARD of less than 0 (ie, anakinra better than usual care) of 61·2%. At day 14, 28 (47%; 95% CI 33 to 59) patients in the anakinra group and 28 (51%; 95% CI 36 to 62) in the usual care group needed ventilation or died, with a posterior probability of any efficacy of anakinra (hazard ratio [HR] being less than 1) of 54·5% (median posterior HR 0·97; 90% CrI 0·62 to 1·52). At day 90, 16 (27%) patients in the anakinra group and 15 (27%) in the usual care group had died. Serious adverse events occurred in 27 (46%) patients in the anakinra group and 21 (38%) in the usual care group (p=0·45).

INTERPRETATION: Anakinra did not improve outcomes in patients with mild-to-moderate COVID-19 pneumonia. Further studies are needed to assess the efficacy of anakinra in other selected groups of patients with more severe COVID-19.

FUNDING: The Ministry of Health, Programme Hospitalier de Recherche Clinique, Foundation for Medical Research, and AP-HP Foundation.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med. 2021. PMID: 33493450. doi:10.1016/S2213-2600(20)30556-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。